Inside The Lupus Pipeline: Reasons For Optimism
Executive Summary
Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.
You may also be interested in...
Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus
Sales of the BLyS inhibitor disappointed at launch, but the franchise is growing double-digits and now a new, more convenient subcutaneous formula will provide another growth opportunity.
UCB's Phase III lupus failure casts further shadow over field
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.
FDA’s Benlysta Approval: A Lesson In Overcoming Unvalidated Endpoints
A novel composite primary endpoint created by Human Genome Sciences with FDA’s blessing helped Benlysta (belimumab) obtain approval for lupus – one of contemporary drug development’s most challenging indications – despite the absence of a standard disease outcome measure.